Clinical trials: Urinary System Tumor
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
NMIBC, MIBC
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
This was a multicenter, prospective, non-interventional, observational cohort study, and the enrolled patients were divided into four cohorts: cohort I was patients with high-risk upper tract urothelial carcinoma (UTUC) (pT3-4 or…
- Conditions
- NMIBC, MIBC, UTUC
- Trial name
- NCT06991868
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Urinary Bladder Neoplasms
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit
The goal of this observational study is to evaluate whether a urinary biomarker (Xpert® Bladder Cancer Detection Test) can be used as a selection tool to decide which patients that should undergo cystoscopy in haematuria work-up…
- Trial name
- NCT06281691
- Testing
- Xpert® Bladder Cancer Detection Test
- Where
- 2 sites in Denmark, Greenland
- Volunteers
- 127 people
- Sponsor
- Jørgen Bjerggaard Jensen
Breast Cancer, Renal Cell Carcinoma
Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)
Everolimus shows a large interpatient variability with fixed dose administration. These very different exposure levels between individuals can result in supratherapeutic or subtherapeutic exposure levels and consequently in over…
- Trial name
- SPOT (NCT02809404)
- Testing
- Everolimus
- Where
- Netherlands
- Volunteers
- 75 people
- Sponsor
- Radboud University Medical Center
Bladder Cancer
The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
This study was a prospective, multicenter observational clinical study, A total of 150 patients with bladder malignant tumor who was admitted to the urology department of each center for treatment and underwent electric resection…
- Trial name
- NCT05096533
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lung Cancer, Head and Neck Cancer
First-in-human Study of S-588210 (S-488210+S-488211)
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
- Conditions
- Lung Cancer, Head and Neck Cancer, Bladder Cancer, Esophageal Cancer
- Trial name
- NCT04316689
- Testing
- S-488210, S-488211
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Shionogi
Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
This is a Phase II/III, open-label, single-arm, multicenter study of intravesical BCG plus N-803 or N-803 only in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC).
- Trial name
- NCT03022825
- Testing
- N-803 and BCG, N-803
- Where
- 28 sites in United States
- Volunteers
- 190 people
- Sponsor
- ImmunityBio, Inc.
Renal Cell Carcinoma
Brivanib Metastatic Renal Cell Carcinoma
This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. This study will evaluate the safety and effectiveness of brivanib in renal cell carcinoma, and explore…
- Trial name
- NCT01253668
- Testing
- Brivanib alaninate, Polymerase chain reaction, Iodine I 124 chimeric monoclonal antibody G250
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Renal Cyst Complex
The Potential of Radiomics to Differentiate Between Malignant and Benign Bosniak 3 Renal Cysts.
More than 200,000 new cases of renal cancer are diagnosed in the world each year, with more than 63,000 new cases in Europe alone.
- Trial name
- BIII (NCT03552497)
- Testing
- Radiomics
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Maastricht University
Prostate Cancer, Urological Cancer
Evaluation of the PI-RADS v2.1 Score Using Multiple Readers
The interpretation of prostate multiparametric MRI (mpMRI) is difficult and requires expertise. As a result, it suffers from substantial inter-reader variability.
- Trial name
- MULTI (NCT04299997)
- Testing
- Assessment of the accuracy of the PI-RADS v2.1 score for predicting the presence of ISUP ≥2 prostate cancer at subsequent biopsy in the dataset of the 171 MRIs for 21 different readers.
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Hospices Civils de Lyon
Kidney Cancers
Clinical Application of CAIX-Targeted PET Imaging in Tumors
According to the 2020 global cancer statistics, renal carcinoma ranks as the fourteenth most common malignant tumor worldwide. In 2020, there were 431,288 new cases and 179,368 deaths from renal cancer, and both the incidence and…
- Trial name
- NCT07590310
- Testing
- Each patient will undergo 68Ga/18F-CAIX-LT-BCH PET/CT imaging, with an administered radioactive dose of approximately 0.05-0.1 mCi/kg.
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University Cancer Hospital & Institute
Renal Cell Carcinoma (RCC)
Tertiary Lymphoid Structures Related Genes Predicting Prognosis in Clear Cell Renal Cell Carcinoma: a Retrospective Cohort Study
The purpose of this research was to uncover the prognostic significance of tertiary lymphoid structures related genes from ccRCC patients with respect to clinical characteristics and outcomes.
- Trial name
- NCT06883565
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Ding-Wei Ye
Bladder Cancer
Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
The study is intended to investigate whether the improved initial detection and resection of bladder cancer lesions in patients with non-muscle invasive bladder cancer with Hexvix (Cysview) fluorescence cystoscopy/TURB will lead…
- Trial name
- NCT01166230
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 551 people
- Sponsor
- Photocure
Bladder Cancer
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts.
- Trial name
- NCT02951767
- Testing
- Atezolizumab
- Where
- 77 sites in United States, Canada and 6 more
- Volunteers
- 119 people
- Sponsor
- Hoffmann-La Roche
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors
This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or…
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT06383507
- Testing
- CHT101
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Renal Cell Carcinoma
The Intrathecal Morphine for Nephrectomy
To evaluate the efficacy and the safety of the intrathecal morphine injection in the open nephrectomy.
- Trial name
- EMPON (NCT01997788)
- Testing
- The intrathecal morphine injection, The intravenous patient-controlled analgesia, Demerol on demand
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Seoul National University Hospital
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003342
- Testing
- filgrastim, carboplatin, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer, Gastric Cancer
Integrated Care Pathway in Oncology (PASSION)
A centralized unit for integrated management of care pathway in Oncology has been created. This unit settles the patients' appointments (biopsy, intravenous device, chemotherapy, imaging, oncologist...).
- Conditions
- Colon Cancer, Gastric Cancer, Pancreatic Cancer, Thoracic Neoplasms
- Trial name
- PASSION (NCT04235556)
- Testing
- Care pathway unit
- Where
- France
- Volunteers
- 1,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bladder Cancer, Bladder Disease
The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation
We try to assess the potential role of telomerase reverse transcriptase and MicroRNA (miR-155) in diagnosis of non-muscle-invasive bladder cancer and their correlation with stage and grade of the tumor.
- Conditions
- Bladder Cancer, Bladder Disease, Bladder Neoplasm, Micro-RNA
- Trial name
- NCT03591367
- Testing
- MicroRNAs-155, Human telomerase reverse transcriptase
- Where
- Egypt
- Volunteers
- 115 people
- Sponsor
- Mansoura University
Bladder Neoplasms
Instillation of Gemcitabine in Patients With Superficial Bladder Cancer
A randomized, double-blind, placebo-controlled Phase 3 multicenter study to assess the efficacy and safety of intravesical instillation of gemcitabine versus placebo immediately after transurethral resection of the bladder tumor.
- Trial name
- NCT00191477
- Testing
- Gemcitabine
- Where
- Germany
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.